

## **Current Report of 14 October 2013**

### **Corrigendum to the interim financial report**

The Management Board of Farmacol S.A reports that in 2013 an amendment was introduced to the manner of presenting part of expenses included previously in the cost of products, goods and materials sold, taking into consideration the specificity and the nature of this group of expenses. The expenses are currently presented by the Group as the costs of sales.

The Farmacol Capital Group interim financial report for the period from 1 January 2013 to 30 June 2013 released on 30 August 2013 did not include any information about the abovementioned manner of presentation; hence it made impossible the comparison with the data from the same period in 2012.

The amendments to the presentation were included in the total income consolidated statement for the period from

1 January 2012 to 30 June 2012 in:

- point B, verse - Cost of products, goods and materials sold
  - It was: PLN 2,085,860 thousand
  - It should be: PLN 2,026.88 thousand
  
- point C, verse - Gross Sales Profit/Loss (A-B)
  - It was: PLN 209,582 thousand
  - It should be: PLN 268,553 thousand
  
- point D, verse - Cost of Sales
  - It was: PLN 127,679 thousand
  - It should be: PLN 186,650 thousand

The Management Board of the Issuer assures that the introduced amendment to the classification of the abovementioned costs did not affect any other costs revealed in the consolidated result of the Farmacol Capital Group for the period from 1 January 2012 to 30 June 2012.

Signatures of duly authorised representatives of the company:

- 1) Barbara Kaszowicz - Acting President of the Management Board
- 2) Adrian Szwenk - Proxy